



[Precise Bio Opens Ophthalmology Facility to Develop 3D Printed Corneas](#)

*Beau Jackson
October 26, 2018*

Precise Bio, a biotechnology company based in North Carolina, has established a dedicated ophthalmology business unit in its Winston-Salem facility. In addition to its 4D Bio Fabrication Platform, the unit aims to advance 3D bioprinting research for the eyes.

“As the first company to transplant a 3D printed corneal graft in animals, we are uniquely positioned to advance the use of bio-printed tissues in ophthalmology,” says Aryeh Batt, Co-Founder and CEO of Precise Bio.

Business - Unit - Potential - Future – Financing

“Establishing a business unit dedicated to realizing this potential will support our future financing strategies and ensure that our financial resources are aligned with the tremendous power of our technology and intellectual property.”

Macro view of the human eye, iris, pupil, eye lashes, eye lids. Photo via Shutterstock.

Batt - Ophthalmology - Market - Value – Bio

According to Batt, the ophthalmology market has an estimated cumulative value of \$10 billion. Precise Bio aims to accelerate the development of autologous cell sourcing, innovative bio-inks, and bioreactors, with an aim to create functional 3D printed organs.

As a result, Precise Bio has developed a laser-assisted 4D bio-fabrication technology platform for cell expansion and the production of complex tissues in a highly reproducible manner. Shay Soker, Co-Founder of Precise Bio and Ph.D., Professor at the Wake Forest Institute of Regenerative Medicine (WFIRM) stated, “[Our] company’s technology overcomes multiple challenges in scalable, reproducible manufacturing of bioprinted tissues and organs, and positions Precise Bio for leadership in the field of regenerative medicine.”

PRECISE - BIO - TECHNOLOGY - POTENTIAL – TO

“PRECISE BIO’S TECHNOLOGY HAS THE POTENTIAL TO TRULY TRANSFORM THE TREATMENT OF SERIOUS DISEASES, AND TO ADDRESS...

[\[Link\]](#)